NRx Pharmaceuticals (NASDAQ:NRXP) Upgraded at Zacks Research

Zacks Research upgraded shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a strong sell rating to a hold rating in a report released on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, February 17th. BTIG Research reaffirmed a “buy” rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Wednesday, February 18th. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, HC Wainwright increased their price target on NRx Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Stock Performance

NRx Pharmaceuticals stock opened at $1.87 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $3.84. The firm has a market capitalization of $59.60 million, a price-to-earnings ratio of -0.80 and a beta of 1.97. The stock’s fifty day moving average is $2.11 and its two-hundred day moving average is $2.51.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Ethos Financial Group LLC purchased a new position in NRx Pharmaceuticals in the third quarter valued at about $39,000. Sjbenen Advisory LLC acquired a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at about $41,000. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after buying an additional 12,950 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter valued at about $107,000. Finally, Two Sigma Investments LP lifted its position in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.